-transparent.png){kind=logo}
Morphine sulfate (MS) and the opioid peptide beta-endorphin beta-LPH-(61-91) stimulate prolactin and growth hormone release in steroid-primed and non-treated male rats when injected intravenously or intracisternally. On a molar basis beta-endorphin is at least 20 times more potent than MS, whereas Met5-enkephalin (beta-LPH-(61-65)) and alpha-endorphin (beta-LPH-(61-76)) are devoid of activity at the dose injected (300 mug). The in vivo stimulatory effects of beta-endorphin on prolactin secretion are reversed by the opiate antagonist naloxone. The absence of in vitro effect of MS and beta-endorphin on prolactin and growth hormone secretion by cultured rat pituitary cells suggest that they have a central nervous system site of action.
C Rivier, and
W Vale, and
N Ling, and
M Brown, and
R Guillemin
January 1977,
Proceedings of the National Academy of Sciences of the United States of America,
C Rivier, and
W Vale, and
N Ling, and
M Brown, and
R Guillemin
July 1982,
Biochemical and biophysical research communications,
C Rivier, and
W Vale, and
N Ling, and
M Brown, and
R Guillemin
September 1998,
Neuroendocrinology,
C Rivier, and
W Vale, and
N Ling, and
M Brown, and
R Guillemin
October 1986,
European journal of pharmacology,
C Rivier, and
W Vale, and
N Ling, and
M Brown, and
R Guillemin
April 1984,
European journal of pharmacology,
C Rivier, and
W Vale, and
N Ling, and
M Brown, and
R Guillemin
December 1981,
Life sciences,
C Rivier, and
W Vale, and
N Ling, and
M Brown, and
R Guillemin
August 1988,
Acta psychiatrica Scandinavica,
C Rivier, and
W Vale, and
N Ling, and
M Brown, and
R Guillemin
October 1980,
Neuroendocrinology,
C Rivier, and
W Vale, and
N Ling, and
M Brown, and
R Guillemin
January 1987,
Psychopharmacology,
C Rivier, and
W Vale, and
N Ling, and
M Brown, and
R Guillemin
July 1992,
Neuroendocrinology,
